EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report

Akinori Sasaki iD, Tomohiro Yamaba, Ayu Tachibana, Rika Kimura, Gaku Uchiyama, Tsubasa Yoshioka, Risa Okamoto

DEN Open · 2026-04 · 6 (1)

DOI: 10.1002/deo2.70189 ↗

Kurz gefasst

Fallbericht in der Zeitschrift DEN Open, online erschienen am 22.08.2025. Verfasst von Akinori Sasaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology Tokyo Bay Urayasu Ichikawa Medical Center Chiba Japan. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, zolbetuximab combined with chemotherapy has been approved as a first‐line treatment for advanced gastric cancer (GC). However, to date, no endoscopic images demonstrating endoscopic complete response (eCR) to zolbetuximab plus chemotherapy have been reported. Herein, we report the case of an 80‐year‐old man who presented with epigastric pain and loss of appetite and was diagnosed with undifferentiated GC and peritoneal metastasis. The patient received modified FOLFOX6 plus zolbetuximab because genetic testing revealed HER2‐negative and claudin 18.2‐positive. He experienced grade 2 nausea, which improved with the administration of antiemetic agents. Computed tomography performed at month 5 showed resolution of peritoneal dissemination. Endoscopic examination during the same period showed the disappearance of the primary gastric tumor with scarring. Biopsy of the scar area revealed only inflammatory cells; therefore, the primary lesion was defined as an eCR. To the best of our knowledge, this is the first report of eCR to zolbetuximab and chemotherapy in a patient with GC and claudin 18.2 positive. This case report suggested that chemotherapy combined with zolbetuximab may offer greater therapeutic benefit than chemotherapy combined with immune checkpoint inhibitors in patients with undifferentiated GC. Further analysis is expected to enable the identification of patients with claudin 18.2‐positive GC in whom zolbetuximab treatment is effective.

Schlagwörter

Stichwörter der Autor:innen

cldn18.2 | endoscopic complete response | gastric cancer | immune checkpoint in…

Autor:innen und Institutionen

  • Department of Gastroenterology Tokyo Bay Urayasu Ichikawa Medical Center Chiba Japan.
  • Department of Oncology Tokyo Bay Urayasu Ichikawa Medical Center Chiba Japan.

ORCID-Profile: Akinori Sasaki

Zitieren

APA

Sasaki, A., Yamaba, T., Tachibana, A., Kimura, R., Uchiyama, G., Yoshioka, T., & Okamoto, R. (2026). Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report. DEN Open, 6(1). https://doi.org/10.1002/deo2.70189

Vancouver

Sasaki A, Yamaba T, Tachibana A, Kimura R, Uchiyama G, Yoshioka T, et al. Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report. DEN Open. 2026;6(1). doi:10.1002/deo2.70189

BibTeX
@article{Sasaki2026,
  author = {Sasaki, Akinori and Yamaba, Tomohiro and Tachibana, Ayu and Kimura, Rika and Uchiyama, Gaku and Yoshioka, Tsubasa and Okamoto, Risa},
  title = {Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report},
  journal = {DEN Open},
  year = {2026},
  volume = {6},
  number = {1},
  doi = {10.1002/deo2.70189}
}
Kostenlos starten →